Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.09T
Market cap1.09T
Price-Earnings ratio
39.76
Price-Earnings ratio39.76
Dividend yield
0.57%
Dividend yield0.57%
Average volume
2.29M
Average volume2.29M
High today
High today
Low today
Low today
Open price
$1,174.51
Open price$1,174.51
Volume
4.13K
Volume4.13K
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$712.05
52 Week low$712.05

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,156.96, giving the company a market capitalization of 1.09T. It carries a P/E multiple of 39.76 and pays a dividend yield of 0.57%.

On 2026-09-24, Eli Lilly(LLY) stock opened at $1,174.51, reached a high of —, and a low of —.

The Eli Lilly(LLY)'s current trading volume is 4.13K, compared to an average daily volume of 2.29M.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

LLY News

TipRanks 11m
Eli Lilly announces FDA approval of Onswik for type 2 diabetes

Eli Lilly (LLY) and Company announced the U.S. Food and Drug Administration approval of Onswik, a once-weekly basal insulin, indicated along with diet and exerc...

Simply Wall St 2h
Eli Lilly Targets Up To Five New Medicines In Research Deal

Eli Lilly (NYSE: LLY) agreed a research collaboration and licensing deal with InnoCare Pharma to pursue up to five new medicines. The partners plan to target s...

Eli Lilly Targets Up To Five New Medicines In Research Deal
Nasdaq 3h
Stanley Druckenmiller, Ken Griffin, and Cathie Wood Have at Least 1 Thing in Common: They All Own This Stock

Key Points Famous investors don’t agree on everything, but these three see the value in this particular healthcare company. This player is generating blockbus...

Stanley Druckenmiller, Ken Griffin, and Cathie Wood Have at Least 1 Thing in Common: They All Own This Stock

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

TipRanks 6h
InnoCare Pharma Strikes Multibillion-Dollar Drug Discovery Pact With Eli Lilly

InnoCare Pharma Ltd. ( (HK:9969) ) has provided an announcement. InnoCare Pharma has entered into a strategic research collaboration and license agreement with...

Nasdaq 17h
Could Retatrutide Be Worth $10 Billion to Eli Lilly?

Key Points Eli Lilly has a deep pipeline in its core therapeutic area. Its next-gen obesity drug, retatrutide, posted excellent results in Phase 3 studies. T...

Could Retatrutide Be Worth $10 Billion to Eli Lilly?
TipRanks 19h
Eli Lilly Expands Selpercatinib Safety Study to India, Eyeing Long-Term Oncology Growth

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Company has launched a new Phase 4 study in India to assess the...

TipRanks 23h
Nektar price target lowered to $50 from $80 at Wedbush

Wedbush lowered the firm’s price target on Nektar (NKTR) to $50 from $80 and keeps a Neutral rating on the shares. Following “speculation on failed litigation”...

Benzinga 1d
Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone

Home Depot Inc. (NYSE:HD) co-founder Ken Langone stated that Mounjaro maker Eli Lilly and Co. (NYSE:LLY) could reach a $2,000 share price within three to four y...

Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone
The Motley Fool 2d
Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems

In some ways, Novo Nordisk (NVO -1.00%) clearly has an image problem. It effectively created the GLP-1 weight-loss drug market when it launched Wegovy. But it q...

Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems
Seeking Alpha 2d
Nektar Therapeutics drops as jury deliberates in Eli Lilly patent dispute over Rezpeg

Nektar Therapeutics (NKTR) quickly sank 11% as a jury deliberated in its patent dispute with Eli Lilly (LLY) over its Rezpeg drug. The jury in San Francisco fe...

Nektar Therapeutics drops as jury deliberates in Eli Lilly patent dispute over Rezpeg

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.